German SynBiotic acquires Croatian Ilesol Pharmaceuticals

The Croatian company is valued at 2.6 million euro ($2.8 million), SynBiotic SE said in a press release last week.

As part of the deal, the share capital of SynBiotic is to be increased by EUR 260,000 as part of a non-cash capital increase. The 260,000 new shares are to be subscribed exclusively by the shareholders of Ilesol Pharmaceuticals.

According to the Croatian court registry, the current shareholders of Ilesol Pharmaceuticals are two Croatian individuals, one Austrian individual and UK company TTS Pharma Limited.

($ = 0.938 euro)